Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Type

Guidance programme 1 selected

Guidance programme

Area of interest

Showing 226 to 250 of 903

TitleReference numberPublishedLast updated
Ravulizumab for treating AQP4 antibody-positive neuromyelitis optica spectrum disorder (terminated appraisal)TA941
Empagliflozin for treating chronic kidney diseaseTA942
Hybrid closed loop systems for managing blood glucose levels in type 1 diabetesTA943
Risdiplam for treating spinal muscular atrophyTA755
Pembrolizumab plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancerTA939
Dupilumab for treating eosinophilic oesophagitis in people 12 years and over (terminated appraisal)TA938
Secukinumab for treating moderate to severe hidradenitis suppurativaTA935
Idecabtagene vicleucel for treating relapsed and refractory multiple myeloma after 3 or more treatments (terminated appraisal)TA936
Tisagenlecleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapies (terminated appraisal)TA933
Foslevodopa–foscarbidopa for treating advanced Parkinson's with motor symptomsTA934
Decitabine–cedazuridine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable (terminated appraisal)TA932
Zanubrutinib for treating chronic lymphocytic leukaemiaTA931
Lutetium-177 vipivotide tetraxetan for treating PSMA-positive hormone-relapsed metastatic prostate cancer after 2 or more treatmentsTA930
Cabozantinib for previously treated advanced differentiated thyroid cancer unsuitable for or refractory to radioactive iodineTA928
Empagliflozin for treating chronic heart failure with preserved or mildly reduced ejection fractionTA929
Ranibizumab for treating diabetic macular oedemaTA274
Mirikizumab for treating moderately to severely active ulcerative colitisTA925
Baricitinib for treating severe alopecia areataTA926
Daratumumab with lenalidomide and dexamethasone for untreated multiple myeloma when a stem cell transplant is unsuitableTA917
Tabelecleucel for treating post-transplant lymphoproliferative disorder caused by the Epstein-Barr virus (terminated appraisal)TA923
Rimegepant for treating migraineTA919
Tofacitinib for treating active ankylosing spondylitisTA920
Ruxolitinib for treating polycythaemia veraTA921
Daridorexant for treating long-term insomniaTA922
Glofitamab for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatmentsTA927

Results per page

  1. 10
  2. 25
  3. 50
  4. All